Clinical Trial Update: To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the relative bioavailability of metformin hydrochloride extended‑release 500 mg tablets under fasting conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Metformin HCl XR Extended-Release Tablets (metformin hydrochloride extended-release)

Snippet

Sponsor: Sandoz | Conditions: Type II Diabetes | Phase 1 | Status: COMPLETED